Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
Celularity (NASDAQ:CELU) has completed a significant balance sheet restructuring, successfully retiring all $41.6 million in senior secured debt, including $32.0 million in principal and $9.6 million in unpaid interest. The company executed this through an Asset Purchase Agreement with Celeniv Pte. Ltd., selling its intellectual property assets while maintaining exclusive licensing rights for 5 years with renewal options.
The transaction included a $33.8 million consideration used to retire debt from RWI and a Promissory Note from Mr. Lim. Additionally, Celularity completed an internal restructuring, creating six wholly-owned subsidiaries for its commercial units: biomaterials, longevity cell therapy, biobanking, contract manufacturing, discovery & development, and asset holding.
Celularity (NASDAQ:CELU) ha completato una rilevante ristrutturazione del proprio bilancio, estinguendo con successo tutto il $41,6 milioni di debito senior garantito, comprensivo di $32,0 milioni di capitale e $9,6 milioni di interessi non pagati. L'operazione è stata realizzata tramite un Asset Purchase Agreement con Celeniv Pte. Ltd., cedendo i propri asset di proprietà intellettuale e mantenendo diritti di licenza esclusiva per 5 anni con opzioni di rinnovo.
La transazione prevedeva una controprestazione di $33,8 milioni utilizzata per estinguere il debito verso RWI e una Cambiale (Promissory Note) emessa dal sig. Lim. Inoltre, Celularity ha completato una ristrutturazione interna, creando sei controllate interamente possedute per le sue unità commerciali: biomateriali, terapia cellulare per la longevità, biobanking, produzione conto terzi, discovery & development e holding degli asset.
Celularity (NASDAQ:CELU) ha completado una significativa reestructuración de su balance, retirando con éxito la totalidad de la deuda senior garantizada de $41,6 millones, incluyendo $32,0 millones de principal y $9,6 millones de intereses impagados. La compañía ejecutó esto mediante un Asset Purchase Agreement con Celeniv Pte. Ltd., vendiendo sus activos de propiedad intelectual y manteniendo derechos de licencia exclusivos por 5 años con opciones de renovación.
La transacción incluyó una contraprestación de $33,8 millones utilizada para cancelar la deuda con RWI y una Pagaré (Promissory Note) del Sr. Lim. Adicionalmente, Celularity completó una reestructuración interna, creando seis subsidiarias de propiedad total para sus unidades comerciales: biomateriales, terapia celular para la longevidad, biobanco, fabricación por contrato, discovery & development y holding de activos.
Celularity (NASDAQ:CELU)는 재무구조를 대대적으로 재편하여 총 $41.6 million의 선순위 담보부 부채를 모두 성공적으로 상환했습니다. 이 금액은 $32.0 million의 원금과 $9.6 million의 미지급 이자를 포함합니다. 회사는 Celeniv Pte. Ltd.와의 자산매매계약(Asset Purchase Agreement)을 통해 지식재산권을 매각하고, 5년간(연장 옵션 포함) 독점 라이선스 권리를 유지하는 방식으로 이를 실행했습니다.
이번 거래에는 RWI 부채와 Lim 씨의 약속어음을 상환하는 데 사용된 $33.8 million의 대금이 포함되었습니다. 또한 Celularity는 내부 구조조정을 완료하여 상업 부문별로 바이오소재, 장수성 세포치료, 바이오뱅킹, 위탁생산, 연구개발(discovery & development), 자산 보유의 여섯 개 전액출자 자회사를 설립했습니다.
Celularity (NASDAQ:CELU) a achevé une importante restructuration de son bilan, procédant au remboursement intégral de la dette senior garantie de $41,6 millions, comprenant $32,0 millions de principal et $9,6 millions d'intérêts impayés. La société a réalisé cette opération via un Asset Purchase Agreement avec Celeniv Pte. Ltd., vendant ses actifs de propriété intellectuelle tout en conservant des droits de licence exclusifs pour 5 ans avec des options de renouvellement.
La transaction comprenait une contrepartie de $33,8 millions utilisée pour solder la dette envers RWI et une reconnaisance de dette (Promissory Note) de M. Lim. De plus, Celularity a mené une restructuration interne, créant six filiales détenues à 100 % pour ses unités commerciales : biomatériaux, thérapie cellulaire de longévité, biobanque, fabrication sous contrat, discovery & development et holding d'actifs.
Celularity (NASDAQ:CELU) hat eine bedeutende Bilanzrestrukturierung abgeschlossen und erfolgreich die gesamte vorrangige besicherte Verschuldung in Höhe von $41,6 Millionen zurückgeführt, darunter $32,0 Millionen Kapital und $9,6 Millionen aufgelaufene Zinsen. Das Unternehmen realisierte dies durch einen Asset Purchase Agreement mit Celeniv Pte. Ltd., verkaufte seine geistigen Eigentumsrechte und behielt exklusive Lizenzrechte für 5 Jahre mit Verlängerungsoptionen.
Die Transaktion umfasste eine Gegenleistung von $33,8 Millionen, die zur Tilgung von Verbindlichkeiten gegenüber RWI und einer Schuldscheinverpflichtung (Promissory Note) von Herrn Lim verwendet wurde. Zusätzlich führte Celularity eine interne Umstrukturierung durch und gründete sechs hundertprozentige Tochtergesellschaften für seine Geschäftseinheiten: Biomaterialien, Langlebigkeits-Zelltherapie, Biobanking, Auftragsfertigung, Discovery & Development sowie Asset-Holding.
- Complete elimination of $41.6 million in senior secured debt from balance sheet
- Retained exclusive licensing rights to intellectual property assets with 5-year renewal options
- Exclusive 5-year repurchase option for the intellectual property assets
- Restructured into six distinct operational subsidiaries for better business unit visibility
- Removed senior secured lenders' general security interest in company assets
- Required to make quarterly license payments for previously owned intellectual property
- Sale of intellectual property assets to external entity
- Dependent on licensing agreement for core intellectual property access
Insights
Celularity eliminates $41.6M debt through IP sale-leaseback deal, significantly improving balance sheet while maintaining operational control.
Celularity has executed a strategic balance sheet restructuring that eliminates
The transaction's mechanics reveal sophisticated financial maneuvering: Celularity sold its intellectual property to Celeniv (a company formed by former lender RWI and Genting Group's executive chairman) for
This restructuring delivers three crucial benefits:
- Eliminates all senior secured debt that would have matured in February 2026, removing near-term refinancing pressure
- Releases the company from the lenders' general security interest in all assets
- Preserves operational control of critical intellectual property through exclusive licensing rights
The concurrent internal reorganization into six discrete subsidiaries aligns with modern corporate finance principles for more transparent business unit accountability. This structure creates clearer operational boundaries between the company's advanced biomaterials, longevity therapeutics, contract manufacturing, and biobanking divisions.
By replacing secured debt with licensing obligations based on monetized IP, Celularity has effectively transformed its liability structure while maintaining operational continuity—potentially opening access to traditional financing sources previously unavailable due to the encumbered balance sheet.
- Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V. Starr and Co., Inc., eliminating all senior secured debt from its balance sheet.
- Entered into an Asset Purchase Agreement with Celeniv Pte. Ltd., or Celeniv, to monetize Celularity intellectual property assets and eliminate senior secured debt. In connection therewith entered into a License Agreement with Celeniv to license back the intellectual property assets on an exclusive basis with an exclusive five-year repurchase option.
- Completed an internal restructuring and realignment to create wholly owned operating subsidiaries for its four commercial businesses—advanced biomaterial products, longevity-focused cell therapy, biobanking, and contract development and manufacturing.
FLORHAM PARK, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, announced today that it has completed a major balance sheet restructuring resulting in the retirement of all
Under the Asset Purchase Agreement, Celularity sold its intellectual property assets to Celeniv, which under the License Agreement licensed those assets to Celularity on an exclusive basis for an initial term of five (5) years renewable for additional five-year terms. Celularity is required to make quarterly license payments to Celeniv under the License Agreement based on the value of the assets sold under the Asset Purchase Agreement. Celularity also has an exclusive five-year option under the Asset Purchase Agreement to repurchase the assets from Celeniv.
Celularity received consideration under the Asset Purchase Agreement in the amount of
“Under the Celeniv agreements announced today, we successfully monetized Celularity’s intellectual property assets to retire the Company’s senior secured debt in its entirety while retaining exclusive use of the assets for our cell therapy, advanced biomaterials, and biobanking businesses. An exclusive five-year right to repurchase those assets from Celeniv gives us additional optionality going forward,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and CEO. “We believe this agreement results in a major improvement of Celularity’s balance sheet with the removal of all the Company’s senior secured debt, which was due for repayment in February 2026, as well as the senior secured lenders’ general security interest in all Company assets. We accomplished this while preserving our exclusive use of intellectual property that is operationally aligned with our programs and commercial activities and expect to gain greater financial flexibility and potential access to lower cost traditional financing sources. We are deeply grateful to both RWI and Mr. Lim for their continued support of Celularity’s mission as we embark on this new chapter.”
Celularity also completed an internal restructuring including establishing operating subsidiaries for each of its functional business units, as follows:
- Celularity Biomaterials LLC, its advanced biomaterial products commercial unit.
- Celularity Longevity LLC, its cellular therapeutics products commercial unit.
- Celularity Advanced Manufacturing LLC, its contract development and manufacturing, or CDMO, commercial unit.
- Celularity Biorepository LLC, its neonatal (Lifebank) and adult cell and tissue banking commercial unit.
- Celularity Discovery & Development, LLC, its internal discovery and development unit.
- Celularity Asset Holding LLC, its internal services unit.
“This internal restructuring formalizes how we manage Celularity to optimize efficiency and financial performance across the Company’s commercial units—advanced biomaterial products, longevity-focused cellular therapeutics, biobanking services, and contract manufacturing and development services—as well as our internal discovery and development unit that supports the four commercial units with new product discovery, development, and technology transfer services, and our internal business services unit. We wanted better visibility around the fact that Celularity operates four commercial businesses under one roof, in contrast to the more typical biotechnology enterprise’s single-shot discovery or development stage programs,” said Dr. Hariri.
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies that target fundamental aging mechanisms like cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.
Forward Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
FAQ
How much debt did Celularity (CELU) retire in its 2025 restructuring?
What are the terms of Celularity's intellectual property agreement with Celeniv?
How many subsidiaries did Celularity create in its 2025 restructuring?
What was the consideration amount Celularity received from Celeniv?
How will the 2025 restructuring affect Celularity's operations?
